PO-0717: Radical cystectomy vs organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review  by Arcangeli, S. et al.
S354                                                                                                                                         3rd ESTRO Forum 2015 
 
 
 
 
Conclusions: SBRT for primary inoperable RCC appears highly 
tolerable in the short to medium term, without need for 
dialysis. No renal dysfunction is observed up to 90 days post-
SBRT, however decline in global GFR is noted at 1-year. Renal 
dysfunction in the treated kidney was highly dose dependent 
and predictable using BED3Gy estimates. Ongoing late 
assessment of renal function kinetics is warranted. 
   
PO-0717   
Radical cystectomy vs organ-sparing trimodality treatment 
in muscle-invasive bladder cancer: a systematic review  
S. Arcangeli1, L. Strigari2, G. Arcangeli2 
1Azienda Ospedaliera San Camillo - Forlanini, Department of 
Radiotherapy and Radiosurgery, Roma, Italy  
2Regina Elena National Cancer Institute (IRE-IFO), Medical 
Physics and Expert Systems Laboratory, Roma, Italy  
 
Purpose/Objective: The objective of the current review is to 
compare 5-year overall survival (OS) rates from retrospective 
and prospective studies of radical cystectomy (RC) and 
trimodality treatment (TMT), i.e. concurrent delivery of 
chemotherapy and radiotherapy after a transurethral 
resection of bladder tumor (TURBT), involving a total of 
10265 and 3131 patients, respectively. 
Materials and Methods: In order to assess the best treatment 
approach for MIBC, a PubMed literature search was 
conducted using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) literature 
selection process. All prospective and retrospective studies 
available in full text, involving more than 20 patients with 
non-metastatic muscle invasive bladder cancer (MIBC) stage 
T2-4a N0 M0, treated with RC or TMT, reporting 5-year 
overall survival (OS) rates were selected. 
Results: The median 5-year OS rate resulted to be 57% in TMT 
group, as compared with 52% (p=0.04), 51% (p=0.02) and 53% 
(p=0-38) in the whole group receiving RC or the group treated 
with RC alone or RC+chemotherapy, respectively. 
Multivariate analysis confirmed TMT as a significant 
prognostic variable. 
Conclusions: Compared with RC, TMT seems to be associated 
with better outcomes for patients with MIBC. The addition of 
chemotherapy may improve the RC outcome in some 
subgroup of patients with higher probability of 
micrometastases. Prospective randomized trials are 
warranted to verify these findings and better define the role 
of the organ-sparing and radical treatment strategy in the 
management of patients with MIBC. 
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Purpose/Objective: Adjuvant hormone therapy (HT) 
combined with radiotherapy (RT) improves prognosis in 
patients with intermediate-high risk prostate cancer (PC). 
However, HT produces several and debilitating side effects. 
There is no clear evidence in literature on the impact of 
integrated RT-HT treatment on QoL and particularly on 
fatigue. Therefore, aim of this study was to analyse the 
impact on QoL of type and duration of HT in patients 
undergoing RT for PC. 
Materials and Methods: Data from 5 clinical studies on RT in 
patients with PC were collected. The QoL was assessed 
before treatment and then after 2 and 5 years from RT 
according to the CLAS scale (CLAS1: quality of life; CLAS2: 
energy level; CLAS3: ability to perform daily activities). 
Average values of these parameters were calculated and 
compared based on HT (administered or not), type of HT 
(analogue vs anti-androgen), and HT duration (< 18 months vs 
≥ 18 months). 
Results: Data from 251 patients with 2 years follow-up and 91 
patients with 5 years follow-up were evaluated. Statistical 
analysis results are shown in the table below. 
 
Conclusions: Based on assessment of QoL in patients 
undergoing adjuvant RT +/- HT for PC, a significant reduction 
of the ability to perform daily activities was observed in 
patients treated with hormone therapy 2 years after RT. The 
lack of significant differences between CLAS values 5 years 
